Registry of the Magellan Robotic System

Peripheral Vascular Disease Clinical Trial

— ROVER  

Official title:

The Robotic Vascular and Endovascular Registry (ROVER)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01984437
• Other study ID #: HMP020
• Status: Terminated
• Phase: N/A
• First received: November 8, 2013
• Last updated: February 27, 2018
• Start date: November 2013
• Est. completion date: August 2016

Study information

• Verified date: July 2016
• Source: Hansen Medical
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The purpose of the registry is to gather both retrospective and prospective case data on the use of the commercially available Magellan Robotic System and Magellan Robotic Catheters in accordance with the approved intended use. For prospective cases, follow-up patient data will be collected at 14 days (± 5 days) post procedure to assess treatment success, primary patency of intended targeted vessel region, and adverse events.

The data will be analyzed for medical education, societal presentation, and/or publication by the investigators.

Over the next 2+ years, physicians who meet the selection criteria will be invited to participate in the registry.

Description:

The objectives of the study are to allow the physician to use the commercially available Magellan Robotic System and Magellan Robotic Catheters to navigate to the treatment targets in the peripheral vasculature to:

• Determine the number of endovascular procedures consecutively performed with the Magellan Robotic System to navigate to treatment targets in the peripheral vasculature and,

• Achieve stable and efficient system preparation and set-up times, navigation and cannulation times of target vessels during endovascular procedures, and placement of therapeutic equipment used to perform endovascular procedures.

• Achieve stable and reduced fluoroscopy time during the endovascular procedures.

• Determine the number of cases required to reach a "steady state," reduction or predictable time in conducting peripheral interventional procedures using descriptive (means, ranges) statistics to analyze the data.

Design

This is a prospective and retrospective, multi-center, single arm, non-blinded, sequentially enrolling data collection activity (for which Hansen Medical is providing funding). Only patients scheduled to undergo endovascular procedures using the Magellan Robotic System will be approached for enrollment.

Methods

Registry procedures will be conducted in accordance with the labeled indication for use of the Magellan™ Robotic System.

Prior to the physician participating in the registry and prior to subject enrollment, all participating physicians will be required to complete Hansen Medical's Magellan Robotic System training.

Participating registry sites must have a commercially available Magellan Robotic System for the treatment of patients.

Data Management

Participating sites will be assigned a specific site numeric identification code by the registry sponsor.

The information collected into the registry will be data related to the procedure in which the Magellan System was used or planned to be used and may include patient follow-up data, minimally 14 days(± 5 days)post procedure but also may include 30 day follow-up to assess for the resolution of a procedural or post procedure adverse event.

The database will be a repository for the collected registry data and the data will be made available (in extractable format) to the physician participants.

Adverse Events

The data submitted will be reviewed on a regular basis for safety issues and complaints.

Adverse events and/or complaints deemed reportable will be submitted to the appropriate regulatory agency/agencies by Hansen Medical, Inc.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 348
• Est. completion date: August 2016
• Est. primary completion date: August 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Must be at least 18 years of age;

2. Able and willing to provide written informed consent;

3. Eligible for minimally invasive or endovascular treatment in the peripheral vasculature;

4. Not participating in an investigational study involving the peripheral vasculature.

Exclusion Criteria:

1. Disease targeted for treatment in the coronary vasculature or intra-cerebral vasculature;

2. Vasculature that cannot accommodate the Magellan™ Robotic Catheter or required accessories;

3. The required delivery of therapeutic device(s) through the Magellan Robotic Catheter in which the diameter for the therapeutic device(s) is/are incompatible with the Magellan Robotic Catheter;

4. An endovascular approach to the treatment of peripheral vasculature disease is contraindicated.

5. Patients who are prisoners.

6. Patients who are mentally incapacitated, e.g., comatose, unresponsive, cannot provide informed consent, or deemed unreliable or unstable by the investigator.

7. Patients with a cognitive impairment.

Related Conditions & MeSH terms

• Peripheral Arterial Disease
• Peripheral Vascular Disease
• Peripheral Vascular Diseases
• Vascular Diseases

Locations

Country	Name	City	State
France	University Hospital of Strasbourg	Strasbourg
Germany	Herz- und Gefäßzentrum Bad Bevensen	Bad Bevensen
United States	Good Samaritan Hospital	Cincinnati	Ohio
United States	Miami Valley Hospital	Dayton	Ohio
United States	The Methodist Hospital	Houston	Texas
United States	Keck Medical Center of USC	Los Angeles	California
United States	Miami Cardiac & Vascular Institute	Miami	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Hansen Medical

Countries where clinical trial is conducted

United States,  France,  Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effectiveness	Consistent manual delivery of therapeutic devices to the target vessel area in the peripheral vasculature by the physician.	14 days post procedure
Primary	Safety	Incidence and description of device-related (Magellan Robotic System only) adverse events through the follow up period.	14 days post procedure